The human costs of cancer and the response of the National Cancer Program

Article Abstract:

The economic cost of cancer in the United States is estimated to be about $83 billion each year. The human cost of cancer is enormous as well, and each year roughly one million Americans will be told they have cancer, and about half will die of their disease. The National Cancer Program is concerned with basic research, the clinical evaluation of cancer treatments, and the management of cancer treatment centers. Often, however, improvements in the early diagnosis and treatment of cancer are not shared equally by all Americans. Poor people have a higher incidence of cancer, and are more likely to die if they develop the disease. Poor patients are less likely to be insured, and are therefore less likely to take advantage of opportunities for early screening, particularly Pap tests and mammography. Each year about 6,000 women die of cervical cancer, and it is thought that many of these lives could be saved with early diagnosis. Breast cancer will cost at least 44,000 lives this year, and it is estimated that 30 percent of these women could be saved if guidelines for mammography were followed. There are other factors that influence cancer mortality. People living in rural areas, and people living in sparsely settled areas of Alaska and Hawaii do not have access to early screening or modern treatment centers. Great advances are being made in a variety of research programs, including the biology of growth factors, the genetics of cancer, and the improvement of chemotherapeutic techniques. The results of this research should benefit all Americans, however, not merely wealthy urban residents. (Consumer Summary produced by Reliance Medical Information, Inc.)

Social aspects, Care and treatment, Medical care, Social policy, Demographic aspects, Medical care, Cost of, Health care costs, Cancer, United States. National Cancer Institute

---

'Chemobrain' in Breast Carcinoma?: A Prologue

Article Abstract:

Cognitive impairment observed before chemotherapy so research must incorporate prechemotherapy assessment to measure effects of chemotherapy on cognitive impairment.

United States, HEALTH SERVICES, Cancer Therapy, Ambulatory Health Care Services, Evaluation, Complications and side effects, Breast cancer, Chemotherapy

---

Similar abstracts:

• Abstracts: Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. Treatment selection for carcinoma of the base of the tongue
• Abstracts: Rationale for different chemotherapeutic and radiation therapy strategies in cancer management. Treatment of clinical Stage I Hodgkin's disease by local radiation therapy alone: a United Kingdom Childrens Cancer Study Group study
• Abstracts: Radiation therapy after breast augmentation or reconstruction in early or recurrent breast cancer. part 2 Symptoms and rehabilitation needs of patients with early stage breast cancer during primary therapy
• Abstracts: Nucleolar organiser regions: new prognostic variable in breast carcinomas. Expression of epidermal growth factor receptor in breast carcinoma
• Abstracts: Ultrasound surveillance of the cervix in twin gestations: management of cervical incompetency. Imaging the fetal brain in the second and third trimesters using transvaginal sonography

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.